Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02185625
Other study ID # AU201407
Secondary ID AU201407
Status Completed
Phase N/A
First received July 1, 2014
Last updated May 18, 2016
Start date July 2014
Est. completion date September 2014

Study information

Verified date July 2015
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Ghana: Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether use of the Safe Delivery smartphone application by midwives can reduce excess blood loss from bleeding, and infant death during childbirth in Ghanaian women. Moreover, it will be investigated whether the Safe Delivery application can increase midwives' knowledge and skills in managing childbirth.

Fifteen hospitals in Greater Accra, Ghana, will be cluster randomized to either use the Safe Delivery application (intervention), or to no intervention (control). In the intervention hospitals, midwives will be educated in the use of Safe Delivery. Pregnant women will be enrolled at delivery and followed until 7 days postpartum. Data collection will begin July 2014 and is expected to be finished by October 2014.


Recruitment information / eligibility

Status Completed
Enrollment 3773
Est. completion date September 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion criteria for Hospitals:

- Located in the region of Greater Accra.

- The hospital should have at least 10 midwives employed.

- The patient flow for each midwife should be at least 10 deliveries per month.

- The annual average number of deliveries should be at least 1,200.

Inclusion criteria for midwives:

- Should have no leave or vacation from June 17th to September 17th 2014.

- Should have a full time employment at the delivery ward (conducting deliveries 100% of the work time).

- Should be willing and available to participate in an information meeting at the hospital where the balloting among eligible midwives will take place.

- Should give an informed consent to participate in the study.

- Should be willing and available to participate in a workshop July 14th 2014 (this is the day of randomization, and intervention midwives will receive smartphone training).

- Should be willing and available to participate in a workshop September 17th 2014 (to complete an end of study questionnaire, the key feature questionnaire, and control midwives will receive smartphones).

- Should be proficient in English to understand the spoken instructions in the animated videos.

Inclusion criteria for women in labor:

- Should be in active labor.

- Should give informed consent to participate in the study.

- Should give birth vaginally.

The women in labor and their newborn children will be the primary observational units.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
Safe Delivery smartphone application
The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.

Locations

Country Name City State
Ghana Achimota Hospital Accra
Ghana Ashaiman Polyclinic Accra
Ghana Ga South Municipal Hospital Accra
Ghana Ga West Municipal Hospital Accra
Ghana Keneshi Polyclinic Accra
Ghana La General Hospital Accra
Ghana Lekma Hospital Accra
Ghana Maamobi General Hospital Accra
Ghana Madina Polyclinic Accra
Ghana Mamprobi Polyclinic Accra
Ghana Ridge Hospital Accra
Ghana Shai Osu Doku District Hospital Accra
Ghana Tema General Hospital Accra
Ghana Tema Polyclinic Accra
Ghana Usher Poly (James Town Maternity Home) Accra

Sponsors (8)

Lead Sponsor Collaborator
University of Aarhus Aase and Ejnar Danielsens Foundation, Augustinus Fonden, Edith and Godtfred Kirk Christiansen Foundation, Lundbeck Foundation, Maternity Foundation, University of Copenhagen, University of Ghana

Country where clinical trial is conducted

Ghana, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postpartum Hemorrhage. Postpartum Hemorrhage is defined as blood loss greater than 500 ml from bleeding associated with childbirth within first 2 hours postpartum. Measurements 2 hours after delivery. No
Secondary Blood loss Amount of blood loss (ml) from bleeding associated with childbirth within first 2 hours postpartum. Measurements 2 hours after delivery. No
Secondary Key feature questionnaire (KFQ). The KFQ questionnaire measures midwives' knowledge in relation to 1) active management of the third stage of labour, 2) treatment of postpartum hemorrhage, 3) manual removal of placenta, and 4) neonatal resuscitation. The midwives' performance will be scored by research assistants by use of the KFQ tool. At baseline and 2 months after randomization. No
Secondary Objective structured assessment of technical skill (OSATS). The OSATS tool measures midwives' skills in relation to 1) active management of the third stage of labour, 2) treatment of postpartum hemorrhage, 3) manual removal of placenta, and 4) neonatal resuscitation. The midwives' performance will be scored by research assistants by use of the OSATS tool. At baseline and 2 months after randomization. No
Secondary Fresh stillbirth Delivery of a fetus with a birth weight above 1,000 g birth weight who at birth has no signs of life (breathing, crying or movement) with intact skin. At delivery. No
Secondary Neonatal mortality 7 days postpartum. A baby born alive with a birth weight above 1000 g who dies within 7 days postpartum. Within 7 days postpartum. No
See also
  Status Clinical Trial Phase
Completed NCT03434444 - In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol N/A
Terminated NCT01980173 - Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care N/A
Not yet recruiting NCT06033170 - Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage N/A
Not yet recruiting NCT02319707 - Management of the Third Stage of Labor Phase 3
Completed NCT02163616 - Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study Phase 3
Recruiting NCT01600612 - Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial N/A
Completed NCT02079558 - Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section Phase 2
Withdrawn NCT01108302 - Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India N/A
Completed NCT00097123 - RCT of Misoprostol for Postpartum Hemorrhage in India N/A
Completed NCT02883673 - Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage N/A
Completed NCT02542813 - Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers Phase 1
Completed NCT04201665 - EMG for Uterotonic Efficiency Estimation N/A
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Not yet recruiting NCT05501106 - Reducing Postpartum Hemorrhage After Vaginal Delivery N/A
Completed NCT05429580 - Prophylactic Tranexamic Acid Use After Vaginal Delivery N/A
Terminated NCT03064152 - Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery N/A
Recruiting NCT05382403 - Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage N/A
Completed NCT02805426 - Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage Phase 4
Completed NCT02910310 - Introduction of UBT for PPH Management in Three Countries N/A
Not yet recruiting NCT02853552 - Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding Phase 4